Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors

Alessandra Gennari, B. Salvadori, Sara Donati, +6

Journal of Clinical Oncology

Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients

Alessandra Gennari, Sara Donati, B. Salvadori, +10

Clinical Breast Cancer

Positron Emission TomographyBreast OncologyOncologic ImagingMedical ImagingMedicine +8

Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years

Valentina Guarneri, Sara Donati, Massimiliano Nicolini, +3

The Oncologist

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, +225

The Lancet Oncology

Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer +5

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

Pierfranco Conté, Alessandra Gennari, Sara Donati, +8

Breast Cancer Research and Treatment

Advanced Breast CancerBreast OncologyMedicinePharmacologyBreast Cancer +5

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Andrea Camerini, C. Puccetti, Sara Donati, +5

BMC Cancer

Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer

Stefano Fogli, Romano Danesi, Alessandra Gennari, +3

Annals of Oncology

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna, +68

The Breast

Victor-6 StudyBreast OncologyOncologyMetronomic TherapyBreast Cancer +7

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

Federico Cappuzzo, Francesca Mazzoni, Alessandra Gennari, +13

British Journal of Cancer

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy

Alessandra Gennari, Paolo Bruzzi, Cinzia Orlandini, +7

British Journal of Cancer